Shares of Portola Pharmaceuticals Inc (NASDAQ:PTLA) have earned a consensus recommendation of “Hold” from the ten ratings firms that are covering the company, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell recommendation, two have given a hold recommendation and six have issued a buy recommendation on the company. The average 12 month price objective among brokers that have issued a report on the stock in the last year is $39.29.
A number of analysts have recently weighed in on the stock. ValuEngine downgraded shares of Portola Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd. Citigroup reduced their target price on shares of Portola Pharmaceuticals from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, October 9th. William Blair restated a “buy” rating on shares of Portola Pharmaceuticals in a report on Friday, August 9th. Credit Suisse Group restated a “neutral” rating and issued a $35.00 target price on shares of Portola Pharmaceuticals in a report on Monday, August 5th. Finally, Cowen restated a “buy” rating and issued a $45.00 target price on shares of Portola Pharmaceuticals in a report on Thursday, August 8th.
Shares of Portola Pharmaceuticals stock traded up $1.05 during trading hours on Monday, reaching $28.36. The company’s stock had a trading volume of 662,500 shares, compared to its average volume of 1,175,239. The firm has a 50 day moving average price of $28.23 and a 200-day moving average price of $29.30. Portola Pharmaceuticals has a one year low of $14.81 and a one year high of $37.95. The company has a debt-to-equity ratio of 453.47, a current ratio of 3.63 and a quick ratio of 3.61. The stock has a market cap of $1.87 billion, a P/E ratio of -5.66 and a beta of 2.09.
Portola Pharmaceuticals (NASDAQ:PTLA) last posted its earnings results on Wednesday, August 7th. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.13. Portola Pharmaceuticals had a negative net margin of 379.94% and a negative return on equity of 352.12%. The firm had revenue of $28.42 million for the quarter, compared to the consensus estimate of $25.42 million. During the same period in the previous year, the firm posted ($1.61) EPS. The business’s quarterly revenue was up 608.7% on a year-over-year basis. As a group, sell-side analysts forecast that Portola Pharmaceuticals will post -3.77 EPS for the current fiscal year.
In related news, Director Hollings Renton sold 5,000 shares of Portola Pharmaceuticals stock in a transaction dated Thursday, August 8th. The shares were sold at an average price of $30.00, for a total transaction of $150,000.00. Following the completion of the transaction, the director now directly owns 18,194 shares of the company’s stock, valued at approximately $545,820. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 4.50% of the stock is currently owned by insiders.
Hedge funds have recently added to or reduced their stakes in the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in Portola Pharmaceuticals by 12.8% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,695 shares of the biopharmaceutical company’s stock valued at $126,000 after buying an additional 533 shares during the period. Advisor Group Inc. boosted its position in Portola Pharmaceuticals by 7.9% in the 2nd quarter. Advisor Group Inc. now owns 9,302 shares of the biopharmaceutical company’s stock valued at $252,000 after buying an additional 681 shares during the period. Empire Life Investments Inc. boosted its position in Portola Pharmaceuticals by 1.6% in the 2nd quarter. Empire Life Investments Inc. now owns 59,159 shares of the biopharmaceutical company’s stock valued at $1,604,000 after buying an additional 940 shares during the period. Valley National Advisers Inc. boosted its position in Portola Pharmaceuticals by 32.0% in the 2nd quarter. Valley National Advisers Inc. now owns 4,046 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 981 shares during the period. Finally, Next Capital Management LLC purchased a new stake in Portola Pharmaceuticals in the 2nd quarter valued at about $27,000.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis and other hematologic disorders and inflammation in the United States. The company offers Andexxa, an antidote for patients treated with rivaroxaban and apixaban when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding; and Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients hospitalized for an acute medical illness.
Read More: After-Hours Trading
Receive News & Ratings for Portola Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.